Although FXR1, its downstream targets, and p53/p21 pathway-mediated cellular senescence are well studied in oral and lung cancer cells, it remains unclear how elevated FXR1 protein enhances malignant transformation in cancer cells. This evidence concerns the gene CDKN1A and lung carcinoma.